

携手同行·共拓新局 | 惠程科技控股子公司锐恩医药与俄罗斯PROMOMED达成战略合作



01

强强联手，见证时刻

Strategic Alliance & Witness Moment



6月17日，上海CPHI世界制药原料展现场气氛热烈。在俄罗斯驻上海总领事馆商务代表 Ermakov Konstantin的共同见证下，惠程科技（Hi Future）控股子公司锐恩医药（Ryan Pharma）与俄罗斯头部创新药企PROMOMED正式签署战略合作协议。这不仅是一场跨国签约，更是一次中俄医药产业优势资源的深度对接。

The atmosphere was electric at CPHI China 2026 in Shanghai on June 17. In a significant stride for Sino-Russian pharmaceutical cooperation, Chongqing Ruien Pharmaceutical (Ryan Pharma), a subsidiary of Hi Future, officially signed a strategic cooperation agreement with PROMOMED, a top-tier Russian innovative pharmaceutical company.

The signing ceremony was jointly witnessed by Mr. Ermakov Konstantin, Commercial Representative of the Consulate General of the Russian Federation in Shanghai. More than just a cross-border contract, this partnership represents a deep alignment of industrial strengths, bridging the complementary advantages of both nations' pharmaceutical sectors.

02

双向赋能，优势互补

Mutual Empowerment & Complementary Strengths



PROMOMED拥有世界级研发中心，打通了从“分子发现”到“制剂生产”的全产业链。集团始终将研发置于战略核心，专注First-in-class首创新药与生物技术药物，是引领俄罗斯医药产业升级的中坚力量。

About PROMOMED

PROMOMED operates world-class R&D centers and commands a fully integrated value chain spanning from molecular discovery to finished dosage manufacturing. With R&D at the core of its strategy, the group dedicates substantial resources to pioneering First-in-class drugs and biotechnological innovations, solidifying its role as the driving force behind the upgrading of Russia's pharmaceutical industry.

锐恩医药是国内中枢神经（CNS）领域的深耕者。作为核心MAH持证企业，锐恩医药手握极具竞争力的CNS管线，深谙中国市场规则与监管逻辑，具备从临床到商业化全流程的“通关”能力。

About Ryan Pharma

A dedicated specialist and long-term contributor in China's Central Nervous System (CNS) therapeutic field, Ryan Pharma is a core Marketing Authorization Holder (MAH) enterprise. With a competitive CNS pipeline and deep mastery of China's regulatory framework, Ryan Pharma delivers end-to-end capabilities—from clinical development through to commercialization—navigating complex market pathways with precision.



03 未来可期，共赢新局

Shared Future & New Horizons

此次合作是惠程科技生物医药板块走向国际化的重要里程碑。未来，双方将紧密协作，将PROMOMED的医药产品与锐恩医药的市场洞察完美融合，持续挖掘合作机遇，拓展业务版图，共同谱写惠及患者的医药新篇章！

This partnership marks a significant milestone in the international expansion of Hi Future's biomedical division. Moving forward, both parties will work in close collaboration to synergize PROMOMED's pharmaceutical excellence with Ryan Pharma's deep market insights. Together, we will continue to unlock new opportunities, expand our global footprint, and write a new chapter in delivering innovative therapies that truly benefit patients worldwide.